These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 20500049

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL, Degeeter M, Nuzum DS, Tzefos M.
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [Abstract] [Full Text] [Related]

  • 4. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS.
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ.
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [Abstract] [Full Text] [Related]

  • 6. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S.
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [Abstract] [Full Text] [Related]

  • 7. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J.
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [Abstract] [Full Text] [Related]

  • 8. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ, Conner C.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [Abstract] [Full Text] [Related]

  • 9. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S.
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [Abstract] [Full Text] [Related]

  • 10. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B.
    Handb Exp Pharmacol; 2011 Oct; (203):53-74. PubMed ID: 21484567
    [Abstract] [Full Text] [Related]

  • 11. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 12. New developments in incretin-based therapies: the current state of the field.
    Robertson C.
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():631-41. PubMed ID: 19900194
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Recent advances in incretin-based therapies.
    Russell-Jones D, Gough S.
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [Abstract] [Full Text] [Related]

  • 15. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK, Cobble ME, Reid TS, Shomali ME.
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [Abstract] [Full Text] [Related]

  • 16. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B.
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [Abstract] [Full Text] [Related]

  • 17. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J.
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of incretin based therapies: clinical trial data.
    White J.
    J Am Pharm Assoc (2003); 2009 Feb; 49 Suppl 1():S30-40. PubMed ID: 19801363
    [Abstract] [Full Text] [Related]

  • 19. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II, Shestakova MV, Sukhareva OIu.
    Ter Arkh; 2010 Feb; 82(10):5-10. PubMed ID: 21341455
    [Abstract] [Full Text] [Related]

  • 20. Differentiating incretin-based therapies for population-based health care.
    Calabrese D.
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.